SEC coupled with in-line multiple detectors for the characterization of an oncolytic Coxsackievirus

Autor: James Z. Deng, Richard R. Rustandi, Andrew Swartz, Yvonne Shieh, Jack B. Baker, Josef Vlasak, Shiyi Wang, John W. Loughney

Publikováno v: Molecular Therapy Oncolytics
Molecular Therapy: Oncolytics, Vol 24, Iss, Pp 139-147 (2022)

V937 is an oncolytic virus immunotherapy clinical drug candidate consisting of a proprietary formulation of Coxsackievirus A21 (CVA21). V937 specifically binds to and lyses cells with over-expressed ICAM-1 receptors in a range of tumor cell types and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c103f8e5c9b3e5c5120a39b6bdc6888a
https://pubmed.ncbi.nlm.nih.gov/35024440

SEC coupled with in-line multiple detectors for the characterization of an oncolytic Coxsackievirus.

Autor: Deng JZ; Analytical Research & Development, Merck & Co., Kenilworth, NJ 07033, USA., Rustandi RR; Analytical Research & Development, Merck & Co., Kenilworth, NJ 07033, USA., Swartz A; Process Research & Development, Merck & Co., Kenilworth, NJ 07033, USA., Shieh Y; Process Research & Development, Merck & Co., Kenilworth, NJ 07033, USA., Baker JB; Analytical Research & Development, Merck & Co., Kenilworth, NJ 07033, USA., Vlasak J; Analytical Research & Development, Merck & Co., Kenilworth, NJ 07033, USA., Wang S; Analytical Research & Development, Merck & Co., Kenilworth, NJ 07033, USA., Loughney JW; Analytical Research & Development, Merck & Co., Kenilworth, NJ 07033, USA.

Publikováno v: Molecular therapy oncolytics [Mol Ther Oncolytics] 2021 Dec 11; Vol. 24, pp. 139-147. Date of Electronic Publication: 2021 Dec 11 (Print Publication: 2022).